An interventional study of Dietary Supplement for Hair Loss in Alopecia, sponsored by Farmoquimica S.A.. Not yet recruiting at 1 site in Brazil. Open to female participants aged 20 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-27.
Sponsored by Farmoquimica S.A. · Not applicable, Interventional, and Prevention
A single-center, open-label clinical study to evaluate whether a dietary supplement can reduce hair loss in women with GLP-1-associated telogen effluvium. Participants will use the supplement for 120 days. Researchers will evaluate hair loss, hair density, and hair growth through clinical assessments, hair measurements (trichogram), and participant questionnaires.
This prospective, single-center, open-label, interventional clinical study is designed to evaluate the efficacy and safety of a dietary supplement in women with telogen effluvium associated with the use of GLP-1 receptor agonists. A total of 48 female participants aged 20 to 60 years will be enrolled. Participants will receive the dietary supplement once daily for 120 days and will attend five study visits at baseline (Day 0) and after 30, 60, 90, and 120 days of supplementation.
The study is based on the hypothesis that nutritional supplementation may help improve hair growth cycle dynamics and reduce hair shedding in participants experiencing GLP-1-associated telogen effluvium. Efficacy will be evaluated using a combination of instrumental, clinical, and participant-reported assessments.
Instrumental evaluation will be performed through trichogram analysis at baseline, Day 60, and Day 120 to assess the distribution of hairs in the anagen and telogen phases and the anagen-to-telogen (A:T) ratio. Clinical assessments will be performed by a dermatologist at each visit using a Visual Analog Scale (VAS) to evaluate hair density, scalp coverage, and hair thinning. Participant-reported outcomes will be collected through structured questionnaires designed to assess perceived changes in hair shedding, hair growth, hair volume, hair strength, hair quality, and overall hair appearance during the supplementation period.
Safety and tolerability will be monitored throughout the study through the collection and evaluation of adverse events. Product adherence will be assessed through participant diaries and product accountability records. The study aims to generate clinical evidence regarding the effects of dietary supplementation on hair loss associated with GLP-1 receptor agonist use under real-world conditions.
511 studies on the registry are indexed under Alopecia; 128 are open to participants now.
This study's planned enrollment of 48 is close to the median of 50 across 430 interventional studies indexed under Alopecia.
Browse Alopecia studies →Farmoquimica S.A. is the lead sponsor of 10 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Female participants with GLP-1-associated telogen effluvium will receive a dietary supplement once daily for 120 days. Efficacy will be evaluated through trichogram analysis, clinical assessments, and participant questionnaires, with safety monitored during the study.
Dietary Supplement: Dietary Supplement for Hair Loss
Dietary supplement containing vitamins, minerals, amino acids, and silicon intended to support hair health and reduce hair loss.
Anagen-to-Telogen Hair Ratio (A:T)
Change in the anagen-to-telogen hair ratio (A:T), assessed by trichogram analysis after 120 days of supplementation with a dietary supplement, compared with baseline (Day 0), in women with telogen effluvium associated with the use of GLP-1 receptor agonists.
Time frame: Baseline and Day 120
Anagen-to-Telogen Hair Ratio (A:T) at Day 60
Change in the anagen-to-telogen hair ratio (A:T), assessed by trichogram analysis after 60 days of supplementation with a dietary supplement, compared with baseline (Day 0).Baseline and Day 60
Time frame: Baseline and Day 60
Change in hair thinning score assessed by Visual Analog Scale (VAS)
Change from baseline in hair thinning score assessed using a 100-mm Visual Analog Scale, where 0 mm indicates absence of hair thinning and 100 mm indicates intense hair thinning. Lower scores represent a better outcome. Assessments will be performed after 30, 60, 90, and 120 days of supplementation.
Time frame: Baseline, Day 30, Day 60, Day 90, and Day 120
Incidence of Adverse Events
Occurrence of adverse events reported during 120 days of continuous use of the investigational product, including assessment of their nature, severity, and relationship to the investigational product.
Time frame: Day 30, Day 60, Day 90, and Day 120
Change in hair density score assessed by Visual Analog Scale (VAS)
Change from baseline in hair density score assessed using a 100-mm Visual Analog Scale, where 0 mm indicates absence of hair density and 100 mm indicates intense hair density. Higher scores represent a better outcome. Assessments will be performed after 30, 60, 90, and 120 days of supplementation.
Time frame: Baseline, Day 30, Day 60, Day 90, and Day 120
Change in perceived hair shedding assessed by a self-perception questionnaire
Change from baseline in participant-perceived hair shedding assessed using a structured self-perception questionnaire. Responses are recorded on a 5-point Likert scale, where 1 = Strongly Disagree, 2 = Disagree, 3 = Neither Agree nor Disagree, 4 = Agree, and 5 = Strongly Agree. Higher scores indicate greater perceived improvement in hair shedding. The frequency and percentage of responses for each score category will be summarized.
Time frame: Baseline, Day 30, Day 60, Day 90, and Day 120
Change in perceived hair strength assessed by a self-perception questionnaire
Change from baseline in participant-perceived hair strength assessed using a structured self-perception questionnaire. Responses are recorded on a 5-point Likert scale, where 1 = Strongly Disagree, 2 = Disagree, 3 = Neither Agree nor Disagree, 4 = Agree, and 5 = Strongly Agree. Higher scores indicate greater perceived improvement in hair strength. The frequency and percentage of responses for each score category will be summarized.
Time frame: Baseline, Day 30, Day 60, Day 90, and Day 120
Change in perceived hair volume assessed by a self-perception questionnaire
Change from baseline in participant-perceived hair volume assessed using a structured self-perception questionnaire. Responses are recorded on a 5-point Likert scale, where 1 = Strongly Disagree, 2 = Disagree, 3 = Neither Agree nor Disagree, 4 = Agree, and 5 = Strongly Agree. Higher scores indicate greater perceived improvement in hair volume. The frequency and percentage of responses for each score category will be summarized.
Time frame: Baseline, Day 30, Day 60, Day 90, and Day 120
Change in perceived hair breakage assessed by a self-perception questionnaire
Change from baseline in participant-perceived hair breakage assessed using a structured self-perception questionnaire. Responses are recorded on a 5-point Likert scale, where 1 = Strongly Disagree, 2 = Disagree, 3 = Neither Agree nor Disagree, 4 = Agree, and 5 = Strongly Agree. Higher scores indicate lower perceived hair breakage and greater improvement in hair resistance. The frequency and percentage of responses for each score category will be summarized.
Time frame: Baseline, Day 30, Day 60, Day 90, and Day 120
Change in perceived overall hair appearance assessed by a self-perception questionnaire
Change from baseline in participant-perceived overall hair appearance assessed using a structured self-perception questionnaire. Responses are recorded on a 5-point Likert scale, where 1 = Strongly Disagree, 2 = Disagree, 3 = Neither Agree nor Disagree, 4 = Agree, and 5 = Strongly Agree. Higher scores indicate greater perceived improvement in the overall appearance of the hair. The frequency and percentage of responses for each score category will be summarized.
Time frame: Baseline, Day 30, Day 60, Day 90, and Day 120
Plan to share: Undecided — This is a preliminary, exploratory clinical study evaluating a dietary supplement intended to support hair health in individuals with telogen effluvium associated with the use of GLP-1 receptor agonists. Individual participant data are not planned to be shared. If the study results are selected for publication, aggregate findings will be reported and made publicly available as appropriate.
No publications or documents are linked to this record.
Start is estimated for Oct 2026; primary completion for Feb 2027, 4 months later.
Of 61 industry-sponsored interventional studies with no phase under Alopecia, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 20. This study's planned 4 months is below that.
Counting every sponsor, half of 146 studies reached it within 12 months; a quarter within 6 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Farmoquimica S.A.